Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Regeneron and Sanofi ride the wave of success; partner again in new cancer antibody deal

Executive Summary

Regeneron Pharmaceuticals Inc. and Sanofi continued to build on a very successful relationship by entering into a new drug development deal, this time focusing on PD-1 and other immuno-oncology antibodies over a period of five years (with the possibility of a three-year extension).
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Co-Promotion
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register